Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 Cell Therapy for COPD With Diffusion Capacity Defect
NCT05638776Phase 2Completed
- Sponsor
- Regend Therapeutics
- Start
- Dec 2022
- Primary completion
- Jul 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in chronic obstructive pulmonary disease (COPD) comparing REGEND001 cell therapy with Placebo (2 arms). Primary endpoint: Responsive rate at 24 weeks. Started Dec 2022; status: completed.
02
Drugs
autologous bronchial basal cells
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05638776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05638776.